Darolutamide

Contraindicated

Darolutamide Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Darolutamide Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Darolutamide Elagolix Orilissa Increased elagolix exposure and an increased risk of elagolix-related adverse reactions Details Darolutamide Ensitrelvir Increased CYP3A/P-gp substrate exposure and an increased risk of adverse reactions Details Darolutamide Grazoprevir Increased grazoprevir exposure and an increased risk of ALT elevation Details Darolutamide Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Darolutamide Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Darolutamide Ranolazine Aspruzyo Reduced ranolazine exposure Details Darolutamide Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Darolutamide Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Darolutamide Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Darolutamide Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Darolutamide Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine Details

Major

Darolutamide Abametapir Increased exposure of CYP3A4 substrate Details Darolutamide Simvastatin Flolipid Increased exposure of OATP1B1 or OATP1B3 substrates Details Darolutamide Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Darolutamide Atogepant Qulipta Altered atogepant exposure Details Darolutamide Atorvastatin Atorvaliq Increased exposure of OATP1B1 or OATP1B3 substrates Details Darolutamide Cariprazine Vraylar Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Darolutamide Amlodipine Amvaz® Reduced amLODIPine exposure Details Darolutamide Axitinib Inlyta Increased exposure of OATP1B1 or OATP1B3 substrates Details Darolutamide Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Darolutamide Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Darolutamide Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Darolutamide Alfentanil Reduced ALfentanil exposure, reduced efficacy of ALfentanil and an increased risk of a withdrawal syndrome Details Darolutamide Apalutamide Erleada Decreased darolutamide exposure Details Darolutamide Artemether Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine, loss of antimalarial efficacy, reduced CYP3... Details Darolutamide Atrasentan Increased atrasentan exposure and an increased risk of atrasentan-related adverse reactions Details Darolutamide Avacopan Tavneos Increased CYP3A4 substrate exposure Details Darolutamide Berotralstat Orladeyo Increased P-gp substrate exposure Details Darolutamide Bosentan Increased exposure of OATP1B1 or OATP1B3 substrates Details Darolutamide Carbamazepine Carbatrol Decreased darolutamide exposure Details Darolutamide Cerivastatin Increased exposure of OATP1B1 or OATP1B3 substrates Details Darolutamide Cholera Vaccine Ipol An increased risk of infection by the live vaccine Details Darolutamide Clarithromycin Biaxin Increased exposure of CYP3A4 substrate and risk for toxicity Details Darolutamide Conivaptan Vaprisol Increased CYP3A substrate exposure Details Darolutamide Docetaxel Beizray Increased exposure of OATP1B1 or OATP1B3 substrates Details Darolutamide Ebola Zaire Vaccine, Live An increased risk of infection by the live vaccine Details Darolutamide Eluxadoline Viberzi Increased eluxadoline exposure Details Darolutamide Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details